Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drugs Fund

This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.

NHS seeks 'solution creators' from within pharma

NHS seeks 'solution creators' from within pharma

There has also been “a degree of convergence”among the people and bodies that work on assessing new medicines, he added, whether they be involved with NICE, the Cancer Drugs Fund

Latest news

  • NICE says OK to Keytruda for bladder cancer via the CDF NICE says OK to Keytruda for bladder cancer via the CDF

    The National Institute for Care and Health Excellence (NICE) has ruled that Keytruda can be made available as an option via the cancer drugs fund (CDF) for treating locally advanced or ... patients in addition to those with non-small-cell lung cancer and

  • Merck and Pfizer set to win NICE backing for Bavencio Merck and Pfizer set to win NICE backing for Bavencio

    with a rare form of skin cancer. ... Additionally, NICE recommended Bavencio should be accessed via the Cancer Drugs Fund (CDF) for those with previously untreated mMCC.

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    That ruling came shortly after the agency also concluded that second-line use of the drug in patients who have failed MabThera therapy should be covered via the Cancer Drugs Fund

  • Unsure on efficacy, NICE passes J&J’s Darzalex to CDF Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

    Johnson &Johnson’s multiple myeloma drug Darzalex has failed to win over NICE for a second time, but will be made available via the Cancer Drugs Fund (CDF) as an interim ... who have failed other drugs for the blood cancer, promoting J&J to ask for a

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    NICE backs Pfizer’ s Xeljanz for RA. But UK’s cost-effectiveness watchdog removes two drugs from CDF. ... Meanwhile, NICE has decided to remove Bayer ’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs

More from news
Approximately 47 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run

  • Opening up market access Opening up market access

    In this PME market access supplement we look at the direction of travel in France and Germany and there’ s an introduction to the UK’ s new-look Cancer Drugs Fund.

  • Opening up market access Opening up market access

    In this PME market access supplement we look at the direction of travel in France and Germany and there’ s an introduction to the UK’ s new-look Cancer Drugs Fund.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.

  • The price is right? The price is right?

    Health stakeholders should focus not on the cost of drugs but on the value they provide. ... Proposed changes to the Cancer Drugs Fund in England include provision for access at a provisional price that is considered potentially cost-effective.

More from intelligence
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest appointments

  • New health ministers and re-appointments after reshuffle New health ministers and re-appointments after reshuffle

    Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the

  • Celgene names general manager for UK and Ireland Celgene names general manager for UK and Ireland

    This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics